ANTIBODY DEVELOPMENT FACILITY

抗体开发机构为弗雷德·哈钦森/华盛顿大学癌症协会提供 (联盟)使用定制设计的单抗和重组(ScFv)抗体的调查人员。完好无损 单抗是通过传统的杂交瘤技术生产的，而重组抗体是 通过噬菌体展示技术产生。含VH和VI链的重组抗体片段 (ScFv)是通过对相关抗原进行生物淘洗而获得的，包括阳性淘洗和阴性淘洗。 技巧。这两种技术的使用使得识别抗体对传统的 蛋白质抗原的生化、细胞生物学和免疫学特征，DNA的产生 疫苗，以及用于识别针对非免疫原性抗体的高通量技术 多肽抗原以及生物标记物的发现(单链抗体抗体阵列)。此应用程序 请求继续支持资源，该资源继续发挥研究的重要作用 财团。

The Antibody Development Facility provides Fred Hutchinson/University of Washington Cancer Consortium (Consortium) investigators with custom designed monoclonal and recombinant (scFv) antibodies. Intact monoclonal antibodies are produced via traditional hybridoma technology while recombinant antibodies are produced via phage display technology. Recombinant antibody fragments containing Vh and VI chains (scFvs) are derived by bio panning on the relevant antigen via both positive and negative panning techniques. Use of both of these technologies has permitted the identification antibodies useful for traditional biochemical, cell biological and immunological characterization of protein antigens, the creation of DNA vaccines, as well as high through put technologies useful for identification of antibodies directed to nonimmunogenic peptide antigens as well as biomarker discovery (scFv antibody arrays). This application requests continued support for a resource which continues to fulfill an essential role for research within the Consortium.